Back to Search Start Over

Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.

Authors :
Percival MM
Lynch RC
Halpern AB
Shadman M
Cassaday RD
Ujjani C
Shustov A
Tseng YD
Liu C
Pergam S
Libby EN
Scott BL
Smith SD
Green DJ
Gopal AK
Cowan AJ
Source :
JCO oncology practice [JCO Oncol Pract] 2020 Sep; Vol. 16 (9), pp. 571-578. Date of Electronic Publication: 2020 May 05.
Publication Year :
2020

Abstract

In January 2020, the first documented patient in the United States infected with severe acute respiratory syndrome coronavirus 2 was diagnosed in Washington State. Since that time, community spread of coronavirus disease 2019 (COVID-19) in the state has changed the practice of oncologic care at our comprehensive cancer center in Seattle. At the Seattle Cancer Care Alliance, the primary oncology clinic for the University of Washington/Fred Hutchinson Cancer Consortium, our specialists who manage adult patients with hematologic malignancies have rapidly adjusted clinical practices to mitigate the potential risks of COVID-19 to our patients. We suggest that our general management decisions and modifications in Seattle are broadly applicable to patients with hematologic malignancies. Despite a rapidly changing environment that necessitates opinion-based care, we provide recommendations that are based on best available data from clinical trials and collective knowledge of disease states.

Details

Language :
English
ISSN :
2688-1535
Volume :
16
Issue :
9
Database :
MEDLINE
Journal :
JCO oncology practice
Publication Type :
Academic Journal
Accession number :
32369409
Full Text :
https://doi.org/10.1200/OP.20.00241